/
FHTX
$4.86+$0.64 (+15.17%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$247.8M
59M shares
52-week range
$3.27 – $6.95
43% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-5.81
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $430.0K | $1.3M | $19.2M | $34.2M | $22.6M | $30.9M |
| Cost of revenue | $379.0K | $1.8M | $57.7M | $0 | $0 | $0 | $0 | $3.3M |
| Gross profit | −$379.0K | −$1.8M | −$57.3M | $1.3M | $19.2M | $34.2M | $22.6M | $27.6M |
| Gross margin | — | — | -13322.1% | 100.0% | 100.0% | 100.0% | 100.0% | 89.2% |
| R&D | $21.2M | $44.4M | $57.7M | $80.3M | $105.6M | $109.7M | $94.5M | $85.5M |
| Operating income | −$26.0M | −$51.1M | −$68.5M | −$100.7M | −$117.1M | −$107.9M | −$102.7M | −$82.1M |
| EBITDA | −$25.6M | −$48.8M | −$67.2M | −$96.2M | −$105.6M | −$90.7M | −$97.2M | −$71.0M |
| Net income | −$26.3M | −$51.1M | −$68.8M | −$101.3M | −$108.9M | −$98.4M | −$86.6M | −$74.3M |
| Net margin | — | — | -16000.0% | -7681.6% | -566.3% | -288.2% | -383.2% | -240.3% |
| EPS (diluted) | -1.34 | -1.40 | -1.90 | -2.78 | -2.62 | -2.34 | -1.58 | -1.18 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $26M | $-1.02 | $-1.29–$-0.81 | 7 |
| 2027 | $37M | $-0.88 | $-1.00–$-0.72 | 7 |
| 2028 | $53M | $-0.58 | $-1.11–$0.31 | 6 |
| 2029 | $80M | $-0.45 | $-0.81–$-0.12 | 4 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Foghorn Therapeutics Inc. Common Stock
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
www.foghorntx.com- Employees
- 106
- IPO / List date
- Oct 23, 2020
- HQ
- CAMBRIDGE, MA
Held by traders on TradeandTell
No one on the platform currently holds FHTX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 406,425 | $1.9M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded FHTX yet.
